Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS). And it is still unclear why cardiac biomarkers would increase in those patients. We hypothesized that excessive phosphorus is account for that phenomenon.To confirm that hypothesis,we used one phosphorus binder to reduce phosphorus absorption in hemodialysis patients for some time and observed the change of cardiac biomarkers of those patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia

NCT01852682

Peritoneal Dialysis Hyperphosphatemia

COMPLETED PHASE3

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

NCT00530114

End Stage Renal Disease Chronic Kidney Disease Hyperphosphatemic +1 more

COMPLETED PHASE2

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01833494

Hemodialysis Patients With Hyperphosphatemia

COMPLETED PHASE3

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01850602

Hemodialysis Hyperphosphatemia

COMPLETED PHASE3

Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

NCT01736150

Chronic Kidney Disease Chronic Kidney Disease on Hemodialysis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular disease is one of the leading causes of morbidity and mortality in patient with chronic kidney disease(CKD), accounting for more than 50% of all deaths.When myocardial cells get injured, cardiac biomarkers will be released into the circulation. Elevated cardiac biomarkers have been observed in patients with various degrees of renal failure. However, the majority of those CKD patients are in the absence of acute coronary syndrome. So far, it is still unclear the mechanisms of the increased biomarkers in CKD patients. Meanwhile, hyperphosphatemia is one of the major features of CKD, particularly of end stage renal disease(ESRD). Lots of evidences have shown that high levels of serum phosphorus and an elevation of the serum calcium × phosphorus product can lead to cardiovascular calcifications and subsequent cardiovascular morbidity and mortality in patients with CKD.it is tempting to hypothesize that hyperphosphatemia may be responsible for the rise of cardiac biomarkers in CKD patients.So we use one phosphate binder to reduce phosphorus absorption in hemodialysis patients for one year and observe the change of cardiac biomarkers of those patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Time of receiving hemodialysis is more than 1 year;
* Hyperphosphatemia before hemodialysis;
* Never use any phosphorus binder in the past 6 months.

Exclusion Criteria

* Receiving coronary artery stent implantation before;
* Having any cardiovascular disease in the past 6 months;
* Cannot tolerate the side effects of phosphorus binder;
* Dose not take medicine according to the prescription;
* inadequate dialysis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No